|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Niveaux de la résilience et tests des différences dans les sous-groupes** | | | | | | | |
|  | | | Résilience | |  |  | t-test | | |
| Variables démographiques et médicales (n) | | | Mean | SD | t | df | Mean difference | 95% CI of difference | p |
| Echantillon (69) | | | 74.35 | (12.61) |  |  |  |  |  |
| General population (Connor & Davidson, 2003) (577) | | | 80.4 | (12.80) | -3.76 | 85.1 | 6.05 | 2.9 ; 9.2 | <0.001\*\* |
| Genre | | |  |  |  |  |  |  |  |
| * Femme (30) | | | 77.7 | (10.63) |  |  |  |  |  |
| * Homme (39) | | | 71.77 | (13.52) | 1.98 | 66 | 5.93 | 0.56 ; 11.92 | 0.052\* |
| Groupes d’âge | | |  |  |  |  |  |  |  |
| < 65 ans (35) | | | 77.94 | (11.55) |  |  |  |  |  |
| * ≥ 65 ans (34) | | | 70.42 | (12.71) | 2.58 | 66 | 7.52 | 1.69 ; 13.35 | 0.012\* |
| Langue | | |  |  |  |  |  |  |  |
| * Français (57) | | | 74.30 | (12.28) |  |  |  |  |  |
| * Allemand (12) | | | 74.58 | (14.66) | -0.71 | 66 | 0.29 | -8.34 ; 7.77 | 0.21 |
| Mode de cohabitation | | |  |  |  |  |  |  |  |
| * Vivre seule (8) | | | 65.75 | (12.52) |  |  |  |  |  |
| * En cohabitation (61) | | | 75.48 | (12.28) | -2.1 | 66 | 9.72 | 0.45 ; 18.62 | 0.039\* |
| Organe d’origine de la tumeur | | |  |  |  |  |  |  |  |
| * Gastrointestinal (16) | | | 68.25 | (13.00) |  |  |  |  |  |
| * Poumon (18) | | | 74.06 | (12.33) |  |  |  |  |  |
| * Sein (10) | | | 81.20 | (9.40) |  |  |  |  |  |
| * ORL (5) | | | 68.20 | (14.82) |  |  |  |  |  |
| * Lymphome (5) | | | 80.60 | (9.63) |  |  |  |  |  |
| * Pancréas (5) | | | 67.6 | (13.96) |  |  |  |  |  |
| * Autres (10) | | | 81.10 | (9.05) |  |  |  |  |  |
| Métastase(s) | | |  |  |  |  |  |  |  |
| * Oui (27) | | | 70.56 | (14.69) |  |  |  |  |  |
| * Non (42) | | | 76.79 | (10.55) | -2.05 | 66 | 6.23 | 0.16 ; 12.30 | 0.044\* |
| Récidive | | |  |  |  |  |  |  |  |
| * Oui (20) | | | 78.30 | (11.24) |  |  |  |  |  |
| * Non (49) | | | 72.73 | (12.89) | 1.69 | 66 | 5.57 | -1.03 ; 12.16 | 0.097 |
| Métastase(s) | | |  |  |  |  |  |  |  |
| * Récidives Oui (11) | | | 77.45 | (13.95) |  |  |  |  |  |
| * Récidives Non (16) | | | 65.81 | (13.63) | 2.16 | 25 | 11.64 | 0.55 ; 22.74 | 0.04\* |
| But du traitement | | |  |  |  |  |  |  |  |
| * Curatif (35) | | | 76.57 | (11.25) |  |  |  |  |  |
| * Palliatif (34) | | | 72.06 | (13.67) | 1.5 | 66 | 4.51 | -1.49 ; 10.52 | 0.14 |
| Type de traitement | | |  |  |  |  |  |  |  |
| * Chimiothérapie (52) | | | 74.15 | (13.26) |  |  |  |  |  |
| * Chimiothérapie et Radiothérapie (17) | | | 74.94 | (10.73) | -2.22 | 66 | 0.79 | -7.87 ; 6.3 | 0.33 |
| \* p<0.05, significatif  \*\* p<0.01, hautement significatif | | |  |  |  |  |  |